{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervix+Neoplasms&page=22", "query": { "condition": "Cervix Neoplasms", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 918, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervix+Neoplasms&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervix+Neoplasms&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T08:43:49.424Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Platinum-resistant Ovarian Cancer", "Post Anti-PD-1 Melanoma", "2L+ Cervical Cancer", "Neoadjuvant Melanoma", "Neoadjuvant Non-Small Cell Lung Cancer", "Post Anti-PD-(L)1 Non-Small Cell Lung Cancer", "Post Anti-PD-(L)1 Small Cell Lung Cancer", "Third Line or Later (3L+) HER2+ Breast Cancer", "Second or Third Line (2L/3L) Cervical Cancer", "Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)" ], "interventions": [ { "name": "TransCon IL-2 β/γ", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy drug", "type": "DRUG" }, { "name": "TransCon TLR7/8 Agonist", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab emtansine (T-DM1)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Ascendis Pharma Oncology Division A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2022-01-11", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 14, "location_summary": "Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05081609" }, { "nct_id": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors", "NSCLC", "HNSCC", "Melanoma", "TNBC", "Esophageal Cancer", "Gastric Cancer", "Cervical Cancer", "Colorectal Cancer", "Urothelial Carcinoma", "Clear Cell RCC", "HCC" ], "interventions": [ { "name": "Enzelkitug", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2022-10-20", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 10, "location_summary": "San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05581004" }, { "nct_id": "NCT03251976", "title": "CPR Decision Aid For Patients With Advanced Gynecologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advance Care Planning" ], "interventions": [ { "name": "video", "type": "BEHAVIORAL" }, { "name": "usual care", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 60, "start_date": "2018-11-06", "completion_date": "2019-05-06", "has_results": false, "last_update_posted_date": "2019-08-19", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03251976" }, { "nct_id": "NCT04266886", "title": "Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Female Reproductive System Neoplasm", "Metastatic Cervical Cancer" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Hypnotherapy", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 152, "start_date": "2018-09-11", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04266886" }, { "nct_id": "NCT00005837", "title": "Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": null, "start_date": "2000-02", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005837" }, { "nct_id": "NCT02595879", "title": "Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cervical Adenocarcinoma", "Advanced Cervical Adenosquamous Carcinoma", "Advanced Cervical Squamous Cell Carcinoma", "Advanced Vaginal Adenocarcinoma", "Advanced Vaginal Adenosquamous Carcinoma", "Advanced Vaginal Squamous Cell Carcinoma", "Stage IB2 Cervical Cancer AJCC v6 and v7", "Stage II Cervical Cancer AJCC v7", "Stage II Vaginal Cancer AJCC v6 and v7", "Stage III Vaginal Cancer AJCC v6 and v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVA Vaginal Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "High-Dose Rate Brachytherapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Triapine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2019-09-18", "completion_date": "2027-04-29", "has_results": true, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Pasadena, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595879" }, { "nct_id": "NCT01031056", "title": "Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastrointestinal Neoplasms", "Gynecologic Cancers", "Gynecologic Cancers Cervical Cancer", "Gastric (Stomach) Cancer", "Gastro-Esophageal(GE) Junction Cancer", "Gastrointenstinal Stromal Tumor (GIST)", "Colon/Rectal Cancer", "Colon/Rectal Cancer Colon Cancer", "Colon/Rectal Cancer Rectal Cancer", "Colon/Rectal Cancer Anal Cancer", "Anal Cancer", "Hepatobiliary Cancers", "Hepatobiliary Cancers Liver", "Pancreatic Cancer" ], "interventions": [ { "name": "Blood Draw", "type": "PROCEDURE" }, { "name": "Frozen Tumor Specimens", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-01", "completion_date": "2099-01", "has_results": false, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01031056" }, { "nct_id": "NCT03104699", "title": "A Study of AGEN2034 in Advanced Tumors and Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Cervical Cancer" ], "interventions": [ { "name": "AGEN2034", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 211, "start_date": "2017-04-11", "completion_date": "2022-06-15", "has_results": true, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03104699" }, { "nct_id": "NCT03786081", "title": "Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Tisotumab Vedotin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 214, "start_date": "2019-02-27", "completion_date": "2026-03-19", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Orange, California • Sylmar, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03786081" }, { "nct_id": "NCT04340011", "title": "Colposcopy Education Using Operant Learning", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Educational Problems", "Cervix, Dysplasia" ], "interventions": [ { "name": "Colposcopy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 250, "start_date": "2020-04-01", "completion_date": "2022-02-01", "has_results": false, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-11-01T08:43:49.424Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340011" } ] }